PET imaging for evaluation of metastatic colorectal cancer of the liver
- PMID: 16457980
- DOI: 10.1016/j.ejrad.2005.11.042
PET imaging for evaluation of metastatic colorectal cancer of the liver
Abstract
Colorectal cancer is a major cause of cancer death in Western Europe and United States; the liver is the most common site for colorectal metastases. PET has an important role in the management of patients with colorectal liver metastases. It is an effective tool to detect hepatic metastases and to monitor the response to systemic and local therapy. The major impact of PET-CT over PET alone is the improvement in the certainty of lesion location. PET-CT has the unique advantage to combine functional and anatomic imaging in an integrated scanner; it allows a thoroughly evaluation of patients with colorectal liver metastases.
Similar articles
-
Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?Ann Surg. 2004 Dec;240(6):1027-34; discussion 1035-6. doi: 10.1097/01.sla.0000146145.69835.c5. Ann Surg. 2004. PMID: 15570208 Free PMC article.
-
Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.Eur J Gastroenterol Hepatol. 2011 Mar;23(3):275-81. doi: 10.1097/MEG.0b013e328343eaa0. Eur J Gastroenterol Hepatol. 2011. PMID: 21304319
-
Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.PET Clin. 2015 Jul;10(3):345-60. doi: 10.1016/j.cpet.2015.03.007. Epub 2015 Apr 18. PET Clin. 2015. PMID: 26099671 Review.
-
Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.Invest Radiol. 2011 Sep;46(9):548-55. doi: 10.1097/RLI.0b013e31821a2163. Invest Radiol. 2011. PMID: 21577131
-
The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.Cancer. 2005 Dec 15;104(12):2658-70. doi: 10.1002/cncr.21569. Cancer. 2005. PMID: 16315241 Review.
Cited by
-
Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer.Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1627-34. doi: 10.1007/s00259-007-0455-9. Epub 2007 May 26. Eur J Nucl Med Mol Imaging. 2007. PMID: 17530248
-
Differentiation between Malignant and Benign Solitary Lesions in the Liver with (18)FDG PET/CT: Accuracy of Age-related Diagnostic Standard.J Cancer. 2015 Jan 1;6(1):40-7. doi: 10.7150/jca.10422. eCollection 2015. J Cancer. 2015. PMID: 25553087 Free PMC article.
-
Diagnostic role of F-18 FDG PET/CT in determining preoperative Lymph node status of patients with rectal cancer: a meta-analysis.Abdom Radiol (NY). 2024 Jun;49(6):2125-2134. doi: 10.1007/s00261-023-04140-4. Epub 2024 Jan 28. Abdom Radiol (NY). 2024. PMID: 38281158 Review.
-
The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1323-9. doi: 10.1007/s00259-008-0743-z. Epub 2008 Mar 18. Eur J Nucl Med Mol Imaging. 2008. PMID: 18347794
-
Selection for hepatic resection of colorectal liver metastases: expert consensus statement.HPB (Oxford). 2013 Feb;15(2):91-103. doi: 10.1111/j.1477-2574.2012.00557.x. HPB (Oxford). 2013. PMID: 23297719 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical